InsiderTrades

Form 4 for SUPN SUPERNUS PHARMACEUTICALS, INC.

Accepted 2024-03-14 00:00:00 ET · period of report 2024-03-12 · accession 0001104659-24-034563 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-03-14 2024-03-12 SUPN Bhatt Padmanabh P. CSO, SVP of IP M - OptEx $12.98 +3,884 12.5K +45% +$50.4K
D 2024-03-14 2024-03-12 SUPN Bhatt Padmanabh P. CSO, SVP of IP S - Sale+OE $32.99 -3,884 8,570 -31% -$128.1K
D 2024-03-14 2024-03-12 SUPN Bhatt Padmanabh P. CSO, SVP of IP M - OptEx $0.00 -3,884 36.1K -10% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-03-12 M A 3,884 $12.98 12,454 D — —
2 Common Common Stock 2024-03-12 S D 3,884 $32.99 8,570 D — — (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.98 to $33.00. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
3 Derivative Employee Stock Option (Right to Buy) 2024-03-12 M D 3,884 $0.00 36,116 D $12.98 · — to 2026-03-01 3,884 Common Stock (F3) The option vested in four equal annual installments beginning on March 1, 2017.